Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 2:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 5,144 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Acquired Immunodeficiency Syndromes Clear all
Completed Phase 2 Interventional

A Multicenter Phase II/III, Placebo-Controlled Study of SNX-111 Administered Intrathecally to Cancer and AIDS Patients With Chronic Pain

NCT00002160
View directory record Official record
Conditions
HIV Infections, Cancer, Pain
Interventions
Ziconotide
Drug
Lead sponsor
Neurex
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
44
States / cities
Huntsville, Alabama • Mobile, Alabama • Northport, Alabama + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 20, 2026, 2:22 PM EDT
Not listed Not applicable Interventional

Comparing the Effectiveness of Two Alcohol+Adherence Interventions for HIV+ Youth

NCT01969461
View directory record Official record
Conditions
HIV
Interventions
Motivational Enhancement Therapy (MET)
Behavioral
Lead sponsor
Wayne State University
Other
Eligibility
16 Years to 24 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Oct 20, 2026, 2:22 PM EDT
Completed Not applicable Interventional

A Technology-based Psychosocial Intervention to Support Social Engagement and Well-being in Older Adults With HIV

NCT06560970
View directory record Official record
Conditions
HIV Diagnosis
Interventions
COPPEhR Intervention, Device-only Control Condition
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
50 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 20, 2026, 2:22 PM EDT
Completed Not applicable Interventional

HIV Prevention and Care of Psychological Trauma in Vulnerable Rwandan Youth

NCT01401335
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, Stress Disorders, Post-Traumatic
Interventions
Questionnaires
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
15 Years to 25 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 25, 2011 · Synced Oct 20, 2026, 2:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

HIV Prevention for Youth With Severe Mental Illness

NCT00496691
View directory record Official record
Conditions
HIV Infections
Interventions
Family-based HIV prevention program
Behavioral
Lead sponsor
Rhode Island Hospital
Other
Eligibility
13 Years to 18 Years
Enrollment
718 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2010
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 20, 2016 · Synced Oct 20, 2026, 2:22 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma

NCT01092182
View directory record Official record
Conditions
Burkitt Lymphoma, Diffuse Large B-cell Lymphoma, c-MYC Positive, Plasmablastic Lymphoma
Interventions
EPOCH-R, EPOCH-RR
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
30
States / cities
La Jolla, California • Los Angeles, California • Atlanta, Georgia + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Oct 20, 2026, 2:22 PM EDT
Completed Phase 1Phase 2 Interventional

BMS-275291 in Treating Patients With HIV-Related Kaposi's Sarcoma

NCT00024024
View directory record Official record
Conditions
Sarcoma
Interventions
rebimastat
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
3
States / cities
Chicago, Illinois • St Louis, Missouri • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 20, 2026, 2:22 PM EDT
Suspended Phase 3 Interventional

A Comparison of Emtricitabine and Abacavir Used in a Three-Drug Combination in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

NCT00002362
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, Efavirenz, Emtricitabine, Stavudine
Drug
Lead sponsor
Triangle Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
10
States / cities
Sacramento, California • San Francisco, California • Fort Lauderdale, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 20, 2026, 2:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I One-month Safety, PK, PD, and Acceptability Study of IVR Releasing TFV and LNG or TFV Alone

NCT02235662
View directory record Official record
Conditions
HIV, Contraception
Interventions
TFV IVR, TFV/LNG IVR, Placebo IVR
Drug · Other
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 11, 2016 · Synced Oct 20, 2026, 2:22 PM EDT
Active, not recruiting Phase 1 Interventional

The Study of Immunization in People Living With HIV Undergoing an ATI for Elicitation of VRC01-lineage Antibodies

NCT06006546
View directory record Official record
Conditions
Chronic HIV Infection
Interventions
426c.Mod.Core-C4b, Adjuvant 3M-052-AF+Alum
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
8
States / cities
Birmingham, Alabama • Atlanta, Georgia • Decatur, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 20, 2026, 2:22 PM EDT
Completed Phase 2 Interventional

Treatment of Patients With Human Immunodeficiency Virus (HIV)-Related Chronic Diarrhea With Saccharomyces Boulardii or Placebo: A Double Blind Trial

NCT00002088
View directory record Official record
Conditions
Diarrhea, HIV Infections
Interventions
Saccharomyces boulardii
Drug
Lead sponsor
Biocodex
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 20, 2026, 2:22 PM EDT
Terminated Phase 1 Interventional

Anakinra, A Recombinant Human IL-1 Receptor Antagonist for Neuroinflammation in HIV-1 Infection

NCT02527460
View directory record Official record
Conditions
HIV Infections, Neurologic Disorders
Interventions
Anakinra
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 61 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Baltimore, Maryland • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 29, 2019 · Synced Oct 20, 2026, 2:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to Two HIV Vaccine Formulations (rMVA-HIV and rFPV-HIV) Alone or in Combination in HIV Uninfected Adults

NCT00083603
View directory record Official record
Conditions
HIV Infections
Interventions
rMVA-HIV (rMVA-HIV env/gag + rMVA-HIV tat/rev/nef-RT), rFPV-HIV (rFPV-HIV env/gag + rFPV-HIV tat/rev/nef-RT), Empty TBC-FPV, TBC-MVA and TBC-FPV
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
4
States / cities
Birmingham, Alabama • St Louis, Missouri • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 20, 2026, 2:22 PM EDT
Not listed Phase 3 Interventional

Comparison of GW433908/Ritonavir to Nelfinavir When Used With Abacavir and Lamivudine in Patients That Have Not Taken Antiretroviral Drugs

NCT00009061
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Abacavir sulfate, Nelfinavir mesylate, Lamivudine, GW433908
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
13 Years and older
Enrollment
624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
37
States / cities
Fountain Valley, California • Los Angeles, California • Sacramento, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 20, 2026, 2:22 PM EDT
Completed No phase listed Observational

Adolescent Master Protocol for Participants 18 Years of Age or Older - Lite

NCT03279185
View directory record Official record
Conditions
HIV/AIDS
Interventions
Not listed
Lead sponsor
Harvard School of Public Health (HSPH)
Other
Eligibility
18 Years and older
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
9
States / cities
Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Oct 20, 2026, 2:22 PM EDT
Completed Phase 3 Interventional Results available

A Study to Compare Effectiveness and Safety of Darunavir/Ritonavir (DRV/Rtv) 800mg/100mg Once Daily Versus DRV/Rtv 600mg/100mg Twice Daily in Early Treatment-Experienced HIV-1 Infected Patients (ODIN)

NCT00524368
View directory record Official record
Conditions
Human Immunodeficiency Virus - Type 1
Interventions
Darunavir (DRV), Ritonavir (rtv)
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
18 Years and older
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
30
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 27 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2013 · Synced Oct 20, 2026, 2:22 PM EDT
Completed Phase 3 Interventional Results available

Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults

NCT02344290
View directory record Official record
Conditions
HIV, Cardiovascular Diseases
Interventions
Pitavastatin, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
40 Years to 75 Years
Enrollment
7,769 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
91
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 59 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Oct 20, 2026, 2:22 PM EDT
Terminated Phase 4 Interventional Results available

Artery Elasticity After Switch From Epzicom to Truvada

NCT00998582
View directory record Official record
Conditions
HIV Infections
Interventions
Tenofovir disoproxil
Drug
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 8, 2012 · Synced Oct 20, 2026, 2:22 PM EDT
Completed No phase listed Observational

Tobacco Assessment and Intervention With Low-Income Persons Living With HIV-AIDS (PLWHA) in Community-Based AIDS Service Organizations

NCT01482923
View directory record Official record
Conditions
Tobacco Cessation, HIV, AIDS
Interventions
Treatment as usual, AIR (Aspirations, Inspiration, Respiration)
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Oct 20, 2026, 2:22 PM EDT
Completed Not applicable Interventional Results available

Pilot Study of a Raltegravir Based NRTI Sparing Regimen

NCT00814879
View directory record Official record
Conditions
Acquired Immune Deficiency Syndrome, AIDS, Human Immunodeficiency Virus, HIV Infections
Interventions
Raltegravir, Atazanavir, Standard treatment regimen
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
5
States / cities
New Haven, Connecticut • Waterbury, Connecticut • West Haven, Connecticut + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Oct 20, 2026, 2:22 PM EDT
Completed Phase 3 Interventional Results available

Study of Lopinavir/Ritonavir Tablets Comparing Once-Daily Versus Twice-Daily Administration When Coadministered With Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-Experienced Human Immunodeficiency Virus Type 1 Infected Subjects

NCT00358917
View directory record Official record
Conditions
Human Immunodeficiency Virus Infections
Interventions
lopinavir/ritonavir (LPV/r) tablet with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
599 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Abbott Park, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 11, 2011 · Synced Oct 20, 2026, 2:22 PM EDT
Completed Phase 4 Interventional Results available

Valganciclovir to Reduce T Cell Activation in HIV Infection

NCT00264290
View directory record Official record
Conditions
HIV Infections, Cytomegalovirus Infections
Interventions
Valganciclovir, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2020 · Synced Oct 20, 2026, 2:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

STI/HIV Intervention Behavioral Intervention Program

NCT04547413
View directory record Official record
Conditions
Sexually Transmitted Infections
Interventions
STI/HIV Intervention Behavioral Intervention Program
Behavioral
Lead sponsor
Madigan Army Medical Center
Federal
Eligibility
18 Years to 30 Years
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
2
States / cities
Fayetteville, North Carolina • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Oct 20, 2026, 2:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Contingency Management for PrEP Adherence and/or Methamphetamine Use

NCT04563962
View directory record Official record
Conditions
Methamphetamine-dependence, HIV-1-infection
Interventions
Contingency Management-ART, Contingency Management-Methamphetamine
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2021 · Synced Oct 20, 2026, 2:22 PM EDT